AIP
MLYS icon

Arrowpoint Investment Partners’s Mineralys Therapeutics MLYS Stock Holding History

Arrowpoint Investment Partners’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$206K Buy
+7,633
New +$209K 0.04% 112
2026
Q1 		– Sell
-6,384
Closed -$232K – 118
2025
Q4 		$232K Buy
+6,384
New +$256K 0.03% 95

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Arrowpoint Investment Partners's MLYS Position: Q2 2026 in Review

Arrowpoint Investment Partners opened a new position in Mineralys Therapeutics (MLYS) in Q2 2026: 7,633 shares worth $206K. The stake represents 0.04% of the portfolio and ranks #112 among its holdings. This is a return to the name: Arrowpoint Investment Partners previously reported a position in MLYS as recently as Q4 2025.

Arrowpoint Investment Partners first reported a position in MLYS in Q4 2025 and has held it in 2 quarters since. The position peaked at $232K in Q4 2025. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Arrowpoint Investment Partners held 7,633 shares of Mineralys Therapeutics worth $206K as of Q2 2026.
  • Mineralys Therapeutics was a new Arrowpoint Investment Partners position in Q2 2026.
  • Mineralys Therapeutics made up 0.04% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #112 holding.
  • Arrowpoint Investment Partners first reported a position in Mineralys Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Arrowpoint Investment Partners's Mineralys Therapeutics position peaked at $232K in Q4 2025.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.